ArticleJournal of human hypertension2006
Plasma adrenomedullin level and development of hypertension.
Article in Journal of human hypertension, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- Associations between symptoms of depression and anxiety with left ventricular hypertrophy among Hispanic/Latino participants of the Hispanic Community Health Study/Study of Latinos.medRxiv : the preprint server for health sciences · 2026Article
- Adrenomedullin in Blood Plasma in Normotensive and Spontaneous Hypertensive Rats: Effect of Increased Blood Viscosity.Bulletin of experimental biology and medicine · 2025Article
- The effects of antihypertensive medications on severity and outcomes of hypertensive patients with COVID-19.Journal of human hypertension · 2023Observational
- Association between MR-proADM concentration and treatment intensity of antihypertensive agents in chronic kidney disease patients with insufficient blood pressure control.Scientific reports · 2021Article
- Article
- Mid-Regional Proadrenomedullin as a New Biomarker of Kidney and Cardiovascular Diseases-Is It the Future?Journal of clinical medicine · 2021Review
- Targeting Adrenomedullin in Oncology: A Feasible Strategy With Potential as Much More Than an Alternative Anti-Angiogenic Therapy.Frontiers in oncology · 2020Review
- Changes of adrenomedullin and natriuretic peptides in patients with adrenal medullary hyperplasia prior to and following pharmacological therapy and adrenalectomy.Experimental and therapeutic medicine · 2016Article
- Vascular endothelial dysfunction and pharmacological treatment.World journal of cardiology · 2015Review
- Plasma concentrations of adrenomedullin and atrial and brain natriuretic peptides in patients with adrenal pheochromocytoma.Oncology letters · 2015Article
- Plasma concentrations of adrenomedullin and natriuretic peptides in patients with essential hypertension.Experimental and therapeutic medicine · 2015Article
- Pathophysiological functions of adrenomedullin and natriuretic peptides in patients with primary aldosteronism.Endocrine · 2015Article
- Adrenomedullin: possible predictor of insulin resistance in women with polycystic ovary syndrome.Journal of endocrinological investigation · 2012Article
- Study of plasma adrenomedullin level in normal pregnancy and preclampsia.Medscape journal of medicine · 2008Article
- Do increased plasma adrenomedullin levels in normotensive subjects precede hypertension?Journal of human hypertension · 2006Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The hypotensive peptide adrenomedullin (AM) is assumed to act as a factor inhibitory on elevation of blood pressure and on progression of the hypertensive organ damage, and plasma AM levels are elevated in patients with hypertension. The aim of the present study is to explore whether or not a rise in plasma AM levels precedes the development of hypertension. Normotensive local residents without apparent cardiovascular or renal disease (n = 177) were divided into low and high AM groups based on the median concentration of AM in plasma (11.9 fmol/ml), and followed up for 3 years for development of hypertension. The incidence of hypertension was higher in the residents with high AM than low AM levels (27.8 vs 11.5%, P < 0.01), whereas a similar analysis of plasma levels of atrial or brain natriuretic peptides revealed no such difference. The plasma AM level was found to be a significant parameter for the development of hypertension in a univariate analysis (P < 0.01), but not in a multivariate analysis. Meanwhile, the plasma AM level was significantly (P < 0.01) correlated with age and body mass index (BMI), two variables independently significant for the development of hypertension. The present findings suggest that an elevation of the plasma AM level associated with aging and increased BMI precedes the development of hypertension in the normotensive subjects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.